Skip to content

Study · Randomized controlled trial · 2016

9 results

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.

Herrmann K, Brunell SC, Li Y, Zhou M, Maggs DG

Advances in therapy12 Apr 2016Cited by 12 (Europe PMC)

PMID27071768 (opens in a new tab)PMCIDPMC4882374 (opens in a new tab)DOI10.1007/s12325-016-0326-5 (opens in a new tab)PepBankPUB-27071768
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, pramlintide reduced HbA1c more than placebo in every disease-duration tertile.

    In plain wordsIn people with type 1 diabetes, pramlintide lowered HbA1c more than placebo across disease durations.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseHbA1c across disease-duration tertiles
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 or 60 µg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In all tertiles, pramlintide resulted in greater reductions in glycated hemoglobin (HbA1c) and weight than placebo, with greater weight reductions and insulin sparing in tertiles 2 and 3.
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, pramlintide reduced weight more than placebo in every disease-duration tertile.

    In plain wordsIn people with type 1 diabetes, pramlintide reduced weight more than placebo across disease durations.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseWeight across disease-duration tertiles
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    30 or 60 µg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In all tertiles, pramlintide resulted in greater reductions in glycated hemoglobin (HbA1c) and weight than placebo, with greater weight reductions and insulin sparing in tertiles 2 and 3.
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.
  3. 03HumanRandomized controlled trialSafety outcome

    In type 1 diabetes, severe hypoglycemia rates were similar with pramlintide and placebo.

    In plain wordsIn people with type 1 diabetes, severe low blood sugar rates were similar with pramlintide and placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSevere hypoglycemia versus placebo
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    30 or 60 µg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Event rates for severe hypoglycemia were similar for pramlintide and placebo and increased with longer duration of diabetes for both groups.
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

Studies that did not test the peptide alone6

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 04HumanNot a test of Pramlintide (Symlin) aloneObservational studyEfficacy outcome

    In pramlintide-treated patients with type 1 diabetes, longer disease duration was associated with greater weight reductions.

    In plain wordsIn people receiving pramlintide, longer diabetes duration was linked to greater weight loss.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseWeight reduction by disease duration
    Study

    n: not reported in source

    Comparator
    shorter disease duration
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    In all tertiles, pramlintide resulted in greater reductions in glycated hemoglobin (HbA1c) and weight than placebo, with greater weight reductions and insulin sparing in tertiles 2 and 3.
    4 context sentences
    Summary · context
    Disease durations for tertiles 1, 2, and 3 were 6.7, 16.5, and 29.9 years, respectively.
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 05HumanNot a test of Pramlintide (Symlin) aloneObservational studyEfficacy outcome

    In pramlintide-treated patients with type 1 diabetes, longer disease duration was associated with greater insulin sparing.

    In plain wordsIn people receiving pramlintide, longer diabetes duration was linked to greater insulin sparing.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseInsulin sparing by disease duration
    Study

    n: not reported in source

    Comparator
    shorter disease duration
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In all tertiles, pramlintide resulted in greater reductions in glycated hemoglobin (HbA1c) and weight than placebo, with greater weight reductions and insulin sparing in tertiles 2 and 3.
    4 context sentences
    Summary · context
    Disease durations for tertiles 1, 2, and 3 were 6.7, 16.5, and 29.9 years, respectively.
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 06HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther

    In type 1 diabetes, baseline HbA1c predicted HbA1c lowering in both pramlintide and placebo groups.

    In plain wordsBaseline HbA1c predicted HbA1c reductions in both pramlintide and placebo groups.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableBaseline HbA1c predictor
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Baseline HbA1c was a predictor of HbA1c lowering in both treatment groups (P < 0.0001)
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 07HumanNot a test of Pramlintide (Symlin) aloneObservational studyOther

    In type 1 diabetes, higher baseline weight predicted greater weight loss in both pramlintide and placebo groups.

    In plain wordsHigher starting weight predicted greater weight loss in both pramlintide and placebo groups.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseBaseline weight predictor
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    higher body weight predicted greater weight loss in both pramlintide- and placebo-treated patients (P < 0.05).
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  5. 08HumanNot a test of Pramlintide (Symlin) aloneObservational studySafety outcome

    Severe hypoglycemia rates increased with diabetes duration in both pramlintide and placebo groups.

    In plain wordsSevere low blood sugar rates increased with diabetes duration in both pramlintide and placebo groups.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseSevere hypoglycemia by disease duration
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Event rates for severe hypoglycemia were similar for pramlintide and placebo and increased with longer duration of diabetes for both groups.
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  6. 09HumanNot a test of Pramlintide (Symlin) aloneObservational studySafety outcome

    In pramlintide-treated patients with type 1 diabetes, longer disease duration was associated with more nausea.

    In plain wordsIn people receiving pramlintide, longer diabetes duration was linked to more nausea.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseNausea by disease duration
    Study

    n: not reported in source

    Comparator
    shorter disease duration
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Nausea with pramlintide increased with longer disease duration.
    3 context sentences
    Summary · context
    This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide.
    Summary · context
    Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratified into tertiles by diabetes duration at baseline.
    Summary · context
    Efficacy and safety end points were assessed at week 26 using analysis of covariance and logistic regression models.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.